Evidence map›Paper›PMID 31858234›Full record

ArticleArchives of gynecology and obstetrics2020

Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma.

Alexander Hein, Michael O Schneider, Simone K Renner, Peter A Fasching, Cornelia Fiessler, Susanna Titz, Arndt Hartmann, Matthias W Beckmann, Falk C Thiel

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of gynecology and obstetrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Alexander HeinDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center, Friedrich Alexander University of Erlangen-Nuremberg, Universitaetsstrasse 21-23, 91054, Erlangen, Germany. alexander.hein@uk-erlangen.de.ORCID http://orcid.org/0000-0003-2601-3398
Michael O SchneiderDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center, Friedrich Alexander University of Erlangen-Nuremberg, Universitaetsstrasse 21-23, 91054, Erlangen, Germany.
Simone K RennerDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center, Friedrich Alexander University of Erlangen-Nuremberg, Universitaetsstrasse 21-23, 91054, Erlangen, Germany.
Peter A FaschingDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center, Friedrich Alexander University of Erlangen-Nuremberg, Universitaetsstrasse 21-23, 91054, Erlangen, Germany.
Cornelia FiesslerDepartment of Medical Informatics, Biometry and Epidemiology, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Susanna TitzDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center, Friedrich Alexander University of Erlangen-Nuremberg, Universitaetsstrasse 21-23, 91054, Erlangen, Germany.
Arndt HartmannInstitute of Pathology, Erlangen University Hospital, Erlangen, Germany.
Matthias W BeckmannDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center, Friedrich Alexander University of Erlangen-Nuremberg, Universitaetsstrasse 21-23, 91054, Erlangen, Germany.
Falk C ThielDepartment of Gynecology and Obstetrics, ALB FILS KLINIKEN GmbH, Klinik am Eichert, Goeppingen, Germany.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEAlb Fils Kliniken · DEUniversitätsklinikum Erlangen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePostmenopausal hormone therapy (HT) is known to affect the development of hormone-dependent endometrial carcinoma (type I EC). Several studies on breast and ovarian carcinoma have shown that HT influences the molecular profile and prognostic behavior of these tumors. This study aimed to investigate the influence of prior HT and other risk factors on the prognosis in a cohort of patients with invasive endometrial carcinoma (EC).

methodsAmong 525 patients diagnosed with EC between 1987 and 2010, 426 postmenopausal patients were identified. Information regarding HT was available in 287 of these patients, 78 of whom had a history of HT and 209 of whom did not. Both overall survival (OS) and progression-free survival (PFS) were analyzed. In addition to OS and PFS, risk factors such as age at diagnosis, postmenopausal HT, body mass index (BMI), diabetes mellitus, tumor stage, EC type (I or II), and recurrences were analyzed.

resultsRelative to HT alone, women with EC and a history of HT had a longer survival than those with no HT. However, the Cox proportional hazards model showed that it was not HT itself, but rather other characteristics in the HT group that were causally associated with longer survival.

conclusionsAge (the older, the worse) and tumor stage (the higher, the worse) were significant influences on overall survival. Patients with HT also had lower BMIs, less diabetes, more type I EC, and fewer recurrences in comparison with the non-HT group. With regard to the PFS, it made no difference whether the patient was receiving HT.

Indexed as

AgedCohort StudiesEndometrial NeoplasmsEstrogen Replacement TherapyFemaleHumansNeoplasm Recurrence, LocalPrognosisRisk FactorsSurvival RateEndometrial carcinomaEstrogenHormone replacement therapyHormone therapyOverall survivalProgesteronePrognosisRisk factors

Identifiers

PMID31858234
OpenAlexW2995892354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.